Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> MELANOMA Latest News

NOV 18, 2013 - Yahoo! News

A Must Read - Share

Merck trial shows more melanoma cancer patients respond to drug

(Reuters) - Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage. The aim of the drugs is to spur the body's own immune system to attack cancer cells. Merck said results from 135 patients whose melanoma had stopped responding to earlier rounds of treatment showed that 41 percent had tumor shrinkage - the rate was 51 percent in the high-dose group, and 40 percent for lowest-dose group.

Tags: Merck trial shows more melanoma cancer patients respond to drug,  Melanoma Latest News